Burn Injury Resource Center
Cumberland Pharmaceuticals Inc. announced in mid-May that results from a clinical study evaluating the safety and efficacy of Caldolor (ibuprofen) given intravenously to treat fever and pain in hospitalized burn patients was published in Volume 32, Number 1 of the Journal of Burn Care & Research.
The study demonstrated that Caldolor significantly reduces fever in these patients, including those with severe thermal burns. The newly published study also supports the safety of Caldolor as it involved the highest dose and duration of exposure to IV ibuprofen to date, demonstrating that the recommended maximum daily dose of 3200 mg/day over five days of treatment was well tolerated.
“Immediate and sustained regulation of body temperature and reduction of fever following a burn injury is critical to patient recovery as well as comfort,” said Dr. John T. Promes, principal investigator of the study, Director of Trauma Services and Associate Director for Surgical Education at Orlando Regional Medical Center.